Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
An account already exists for this email address, please log in.
Gamble of the week: Mood turns sour on artifical sweeteners
A profit warning has sent investors running for cover, says Phil Oakley. But there's still much to like about this maker of artificial sweetners.
One of the best times to buy a share is when it is very unpopular and the price is depressed. If the reason for the shares being depressed is temporary and can be reversed, then buying can reward patient investors.
But too often this point is overlooked and people end up catching the proverbial falling knife, finding out later that the shares were not that cheap after all. Shares in bad businesses usually have low price tags for a good reason.
This is the problem facing prospective buyers of shares in this artificial sweetener makerright now. A few weeks ago the company issued a profits warning and its shares have been hammered.
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
The prices it can charge for its sucralose artificial sweetener, Splenda, are expected to fall by 15% this year due to large stocks of Chinese products flooding the market. Profits from Splenda, which account for about 20% of Tate & Lyle's(LSE: TATE) earnings, will take a big hit.
All this is unfortunate as it masks the good things that are going on elsewhere. Tate & Lyle has some good products that could be very useful in combating the global obesity crisis (my colleague Matthew Partridge wrote about these in the magazine a couple of weeks ago).
In particular, its intense sweeteners Tasteva, which is based on stevia, and Purefruit, based on monk fruit, could have a lot of potential. Elsewhere, the company is also doing well with its speciality starches and low sodium salt substitute, which promote healthy living.
If the sales of these products can grow strongly over the next few years, thenthey will form a bigger part of the company's profits and help lessen the worries about Splenda. They could also help Tate's total profits to start growing again.
Tate & Lyle shares look like they could fall further, as it seems likely that they will be relegated from the FTSE 100 index this week. This means that FTSE 100 tracker funds will have to sell them and push down the share price.
This could be good news for prospective buyers. Tate & Lyle shares look reasonably valued at just under 12 times forward earnings and offer a yield of 4.4% on a dividend that is expected to keep on growing. The company also appears to have strong finances. The shares look worth a punt.
Verdict: buy at 640p
Sign up for MoneyWeek's newsletters
Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
